New Data Confirming Patient Satisfaction, Safety, Efficacy and Reduction of Hospital Readmissions with ActiveCare® Mobile Compression Device Following Joint Replacement Surgery Presented at AAOS Annual Meeting

LAS VEGAS, March 27, 2015 /PRNewswire/ --

Medical Compression Systems, Inc. (MCS) today announced new data further validating the use of the ActiveCare® DVT prophylaxis compression system following total joint replacement procedures. The study, selected as the best poster in the adult reconstruction category, was presented this week at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, taking place in Las Vegas from March 24-28.

     (Logo: http://photos.prnewswire.com/prnh/20150327/736397 )

"These encouraging results demonstrate that using a mobile compression device offers comparable efficacy for preventing thromboemboli, while introducing a significantly lower risk of associated complications," said Ryan M. Nunley, M.D., associate professor of orthopedic surgery at the University of Washington School of Medicine in St. Louis. "Furthermore, issues associated with drainage, bleeding events and wound problems were significantly lower in the standard risk patient group, which are critical factors that contribute to an overall higher level of patient satisfaction and reduced hospital readmissions."

The study was designed to prospectively evaluate the safety and efficacy of the ActiveCare® mobile compression device and warfarin for preventing VTE post-operatively, and to monitor patient satisfaction following each treatment regimen. Among 2,722 participants, 1,888 received standard-risk therapy and 834 received high-risk therapy. Standard risk patients wore ActiveCare® for 10 days following elective total joint replacement of the hip or knee and took aspirin 325 mg twice daily for six weeks post-operatively. High-risk patients received adjusted-dose warfarin for four weeks and wore compression stockings for six weeks post-operatively.

Patients were followed prospectively for six months and monitored for bleeding complications, symptomatic VTEs, hospital readmissions and patient satisfaction with the two VTE prophylaxis treatment approaches. The rate of VTEs at 4-6 weeks were nearly identical in the standard risk and high risk groups (0.6% and 0.4% respectively) and no differences were found based on the type of joint replacement procedure. Drainage of greater than or equal to four days, rate of major bleeding events, and rate of wound problems were significantly higher in the high-risk group than in the standard group (21% vs. 14% (p<0.001), 2.0 vs. 0.3% (p<0.001) and 1.3% vs. 0.2% (p=0.002) respectively). Patients who were treated with ActiveCare® were consistently more satisfied at 2 weeks and at 4-6 weeks vs. those who received high-risk anticoagulation therapy.

"These study results add to a growing body of evidence demonstrating that ActiveCare® is clinically equivalent to anticoagulant therapy for preventing VTE post-operatively, with a significant decrease in complications and a high degree of patient satisfaction," said Timothy A. McCarthy, chief executive officer, MCS. "As part of our ongoing efforts to support the needs of the orthopedic surgery community to deliver outstanding clinical results in the most cost-effective manner possible, we are actively working with scientific investigators to conduct additional research to not only reinforce the outstanding DVT prophylaxis ActiveCare® delivers, but also to further demonstrate the value our offering brings to the entire health care system."

About Venous Thromboembolism 

Venous thromboembolism (VTE) is a condition that includes both deep vein thrombosis (DVT), a blood clot in a deep vein in the lower extremities, and pulmonary embolism (PE), where the blood clot becomes dislodged and migrates to the lungs. In the United States and the United Kingdom, VTEs kill more people than AIDS, breast cancer, prostate cancer and traffic accidents combined. VTEs are the most common complication following total joint replacement procedures.

About ActiveCare® 

ActiveCare® is developed and manufactured by Medical Compression Systems, a leader in innovative, non-invasive solutions for the prevention of deep vein thrombosis (DVT). The company is the first and only one to offer the healthcare market a new class of therapy in combination with MCS's patented Synchronized Flow Technology (ActiveCare® + S.F.T.) device, which can reduce the risk of bleeding complications, thus improving the standard of health care. ActiveCare®, a non-pharmaceutical, mobile compression device, provides effective and safe prevention against deep vein thrombosis (DVT) in the hospital and home care settings, while uniquely monitoring patient compliance. ActiveCare® fully meets the American College of Chest Physicians' Evidence-Based Clinical Practice Guidelines (ACCP 2012) to prevent DVT after total joint replacement for the duration of treatment, from hospital to home.

About MCS Medical Compression Systems 

Founded in 1997, MCS Medical Compression Systems (Ltd.) is an Israeli public company traded on the Tel Aviv Stock Exchange (TASE: MDCL).  MCS Inc., the company's subsidiary, is located in the USA. For more information, please visit http://www.activecare.mcsmed.com.

Contact:
Ms. Tlalit Bussi Tel-Tzure, VP Sales & Marketing
Email: [email protected]
Phone: +(972)54-565-0737

SOURCE MCS Medical Compression Systems